Invited Commentary on: Can CD44+/CD24- Tumor Stem Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy?
Open Access
- 1 January 2011
- journal article
- Published by Korean Breast Cancer Society in Journal of Breast Cancer
- Vol. 14 (3) , 251-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtypeJournal of Clinical Pathology, 2011
- Can CD44+/CD24- Tumor Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy?Journal of Breast Cancer, 2011
- Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast CancerClinical Cancer Research, 2010
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersNature Medicine, 2009
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to ChemotherapyJNCI: Journal of the National Cancer Institute, 2008
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Sometimes a Great Notion--An Assessment of Neoadjuvant Systemic Therapy for Breast CancerJNCI: Journal of the National Cancer Institute, 2005
- Stem cells in normal breast development and breast cancerCell Proliferation, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003